reports
Hain Celestial Announces Fiscal Third Quarter 2025 Results Conference ...
Hain Celestial Announces Fiscal Third Quarter 2025 Results Conference Call and Webcast HOBOKEN, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Hain Celestial Group (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, plans to issue its financial results for the fiscal third quarter before the market opens on Wednesday, May 7, 2025. The company will host a conference call, which will be webcast, to discuss the results at 8:00 AM ET. Speaking on behalf of Hain Celestial will be Wendy Davidson, President and Chief ...
Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medi...
EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East." The report surveyed over 2,500 people, made up of individuals with Type 2 diabetes and healthcare professionals, from Germany, Italy, the Netherlands, Saudi Arabia, Spain and the United Kingdom. The findings provide valuable insights into access to care and perceptions of diabetes technology. During the conference, first-ever accuracy a...
- Research Team ACF
ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...
Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...
VRTX VERTEX PHARMACEUTICALS INCORPORATED
TDOC TELADOC HEALTH INC.
PODD INSULET CORPORATION
ORMP ORAMED PHARMACEUTICALS
MDT MEDTRONIC PLC
LLY ELI LILLY AND COMPANY
SAN SANOFI
TILS TIZIANA LIFE SCIENCES
CRSP CRISPR THERAPEUTICS AG
SENS SENSEONICS HOLDINGS
TNDM TANDEM DIABETES CARE
NOVO NOVO NORDISK A/S-B
SANA SANA BIOTECHNOLOGY
HIMS HIMS AND HERS HEALTH INC (A)
KDST.TA:TASE KADIMASTEM
NLSP:NasdaqCM NLS PHARMACEUTICS
CRSP (NASDAQ) CRISPR THERAPEUTICS
TLSA TIZIANA LIFE SCIENCES LTD
Dexcom Appoints Renée Galá to Board of Directors
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025. Ms. Galá is an accomplished executive with significant financial, strategic and operational leadership experience across the life sciences sector. She currently serves as President and Chief Operating Officer of Jazz Pharmaceuticals Public Limited Company, a global biopharmaceutical company with greater than $4 billion in total revenues in 2024 whose purpose is to innovate to transform the lives of p...
Dexcom Announces Upcoming Conference Presentation
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that management will present an update on the company at the 46th Annual Raymond James Institutional Investors Conference on Tuesday, March 4th. The live presentation is scheduled to begin at approximately 10:25 AM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneere...
Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Revenue grew 8% year-over-year to $1.114 billion on a reported basis and 8% year-over-year on an organic1 basis. U.S. revenue grew 4% and international revenue grew 17% on a reported basis and 19% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $188.9 million or 17.0% of revenue, a decrease of 400 basis points compared to the fourth quarter of 2023. Non-...
Hain Celestial Reports Fiscal Second Quarter 2025 Financial Results
Hain Celestial Reports Fiscal Second Quarter 2025 Financial Results Strong Operating Cash Flow and Reduction in Debt; Positioned to Pivot to Growth in Back HalfExploring Strategic Options for Personal Care Category HOBOKEN, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Hain Celestial Group (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, today reported financial results for its fiscal second quarter ended December 31, 2024. “Despite challenges in the quarter, we generated strong operating cash flow and fur...
Dexcom Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release ...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2024 financial results after market close on Thursday, February 13, 2025. Management will hold a conference call to review the company's fourth quarter and fiscal year 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at and will be archived there for future reference. To listen to the conference call, please dial (888) 4...
Hain Celestial Announces Fiscal Second Quarter 2025 Results Conference...
Hain Celestial Announces Fiscal Second Quarter 2025 Results Conference Call and Webcast HOBOKEN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Hain Celestial Group (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, plans to issue its financial results for the fiscal second quarter before the market opens on Monday, February 10, 2025. The company will host a conference call, which will be webcast, to discuss the results at 8:00 AM ET. Speaking on behalf of Hain Celestial will be Wendy Davidson, President and Ch...
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter a...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the fourth quarter of 2023. U.S. revenue is expected to be approximately $803 million, representing growth of 4% over the fourth quarter of 2023. International revenue is expected to be approximately $310 million, an increase of 17% over the fourth quarter of 2023. For fiscal 2024, total preliminary, unaudited revenue is approximately $4.032 billion, an increase of 11% over 2...
Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025. The live presentation is scheduled to begin at approximately 12:00 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the sta...
Dexcom Launches the First Generative AI Platform in Glucose Biosensing
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first CGM manufacturer to integrate GenAI into glucose biosensing technology.1 The new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between lifestyle choices and glucose levels while providing actionable insights to help improve metabolic health. , the first over-the-counter glucose biosensor cleared2 by the FDA in the United States, is the first Dexcom product...
Alberta Government Lifts Age Restrictions on Continuous Glucose Monito...
BURNABY, British Columbia--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the eligibility criteria* to also include adults ages 18 and older. This press release features multimedia. View the full release here: Alberta residents living with type 1 or type 2 diabetes who meet the eligibility criteria are now covered for Dexcom G7 (Photo: Business Wire) Alberta res...
Dexcom and ŌURA Announce Strategic Partnership
SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)-- (NASDAQ:DXCM), the global leader in glucose biosensing, and , maker of the world’s leading smart ring, announced today a strategic partnership to help millions of people improve their metabolic health through the integration of Dexcom glucose data with vital sign, sleep, stress, heart health and activity data from Oura Ring. Combining Dexcom glucose data with the biometrics collected by Oura Ring will provide users of both products with a more complete picture of overall health. Dexcom is also making a $75 million strategic investment in ŌURA Serie...
Dexcom Helps People With Diabetes Take the First Step to Discover What...
SAN DIEGO--(BUSINESS WIRE)-- This World Diabetes Day, (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first step to discover what they’re made of. This comes as global data1 shows nearly 70% of people with diabetes say they didn’t know where to begin their health journey when they were first diagnosed, and nearly half said diabetes has limited their ability to pursue a passion or interest. This press release features multimedia. View the full release here: Dexcom is teaming up with its thousands of global brand advo...
Hain Celestial To Participate in Upcoming Investor Conferences
Hain Celestial To Participate in Upcoming Investor Conferences HOBOKEN, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Hain Celestial Group (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, today announced participation in two upcoming investor conferences. On November 19, 2024, Lee Boyce, Chief Financial Officer, will host investor meetings at the Jefferies Miami Consumer Conference. On November 20, 2024, Wendy Davidson, President and Chief Executive Officer, will participate in a fireside chat at 10:00 a.m...
Hain Celestial Reports Fiscal First Quarter 2025 Financial Results
Hain Celestial Reports Fiscal First Quarter 2025 Financial Results Company Positioned for Growth, Reaffirms Fiscal 2025 Guidance HOBOKEN, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Hain Celestial Group (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, today reported financial results for its fiscal first quarter ended September 30, 2024. “Our performance in the first quarter built upon the momentum from our foundational year by further streamlining our portfolio and operational footprint, enabling us to...
Dexcom Reports Third Quarter 2024 Financial Results
SAN DIEGO--(BUSINESS WIRE)-- (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: Revenue grew 2% year-over-year to $994.2 million on a reported basis and 3% year-over-year on an organic1 basis. U.S. revenue declined 2% and international revenue grew 12% on a reported basis and 16% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $152.0 million or 15.3% of revenue, a decrease of 580 basis points compared to the third quarter of 2023. Non-GAAP operating income* of $21...
Hain Celestial Announces Fiscal First Quarter 2025 Results Conference ...
Hain Celestial Announces Fiscal First Quarter 2025 Results Conference Call and Webcast HOBOKEN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Hain Celestial Group (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, plans to issue its financial results for the fiscal first quarter before the market opens on Thursday, November 7, 2024. The company will host a conference call, which will be webcast, to discuss the results at 8:00 AM ET. Speaking on behalf of Hain Celestial will be Wendy Davidson, President and Chi...
Dexcom, Beyond Type 2 and Retta Establish National Glucose Awareness W...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, in partnership with the nonprofit , are teaming up with author, producer and actress Retta to establish National Glucose Awareness Week from Sept. 23-29, 2024. will help close the glucose knowledge gap and encourage people to take action to own their glucose health. This press release features multimedia. View the full release here: Actress Retta teams up with Dexcom and Beyond Type 2 to establish National Glucose Awareness Week. (Photo: Business Wire) Understand...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.